Oncotelic Therapeutics Balance Sheet Health
Financial Health criteria checks 0/6
Oncotelic Therapeutics has a total shareholder equity of $8.1M and total debt of $12.9M, which brings its debt-to-equity ratio to 159.1%. Its total assets and total liabilities are $26.8M and $18.7M respectively.
Key information
159.1%
Debt to equity ratio
US$12.94m
Debt
| Interest coverage ratio | n/a |
| Cash | US$149.02k |
| Equity | US$8.13m |
| Total liabilities | US$18.65m |
| Total assets | US$26.78m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: OTLC's short term assets ($239.0K) do not cover its short term liabilities ($16.4M).
Long Term Liabilities: OTLC's short term assets ($239.0K) do not cover its long term liabilities ($2.3M).
Debt to Equity History and Analysis
Debt Level: OTLC's net debt to equity ratio (157.2%) is considered high.
Reducing Debt: OTLC's debt to equity ratio has increased from 10.2% to 159.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OTLC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OTLC has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.3% each year.